Insurance Denied Genetic Testing? How to Appeal BRCA, Hereditary Cancer Panel, and Preventive Testing Denials

Genetic testing for hereditary cancer syndromes — including BRCA1/2 mutations (breast and ovarian cancer), Lynch syndrome (colorectal, endometrial, and other cancers), and multi-gene hereditary cancer panels — can be life-saving. Early identification of high-risk individuals allows for enhanced surveillance, preventive surgery, and chemoprevention that dramatically reduces cancer incidence and mortality. Yet insurance denials for genetic testing are common, often based on narrow coverage criteria that fail to reflect current clinical guidance.

If your genetic test was denied, here is how to appeal effectively.

Common Genetic Testing Denial Reasons

Not meeting specific personal or family history criteria. Most insurers apply criteria based on personal cancer history, age at diagnosis, and family history patterns. If a patient does not meet the specific point-based criteria in the insurer's policy, the test is denied — even when a genetic counselor has identified a clinically significant risk pattern.

Testing classified as "investigational." Multi-gene hereditary cancer panels (testing 25–80 genes simultaneously) are sometimes classified as investigational despite strong evidence and widespread clinical adoption. The National Comprehensive Cancer Network (NCCN) and major cancer centers routinely use these panels.

Preventive testing not covered under the medical benefit. Some insurers route genetic testing for preventive purposes to a different benefit tier, resulting in different cost-sharing or coverage rules. ACA preventive care mandates are relevant here.

Genetic counseling denied as a prerequisite. Some plans require pre-test genetic counseling from a credentialed genetic counselor, but then deny coverage for the counseling itself — creating a Catch-22.

Cascade testing of at-risk family members denied. When a pathogenic variant is found in an affected family member, cascade testing of at-risk relatives is often denied, despite being both clinically indicated and cost-effective.

Variant of uncertain significance (VUS) follow-up denied. If a variant of uncertain significance is identified, follow-up testing of family members may be denied even though this helps clarify clinical significance.

Common denial codes: CO-50 (not medically necessary), CO-96 (non-covered charge), CO-B13 (medical necessity criteria not met), B15 (authorization not obtained).

The ACA Preventive Care Mandate and USPSTF Recommendations

The Affordable Care Act (ACA) Section 2713 requires non-grandfathered health plans to cover USPSTF "A" and "B" grade preventive services without cost-sharing. This is one of the most powerful tools in genetic testing appeals.

The U.S. Preventive Services Task Force (USPSTF) has issued recommendations directly applicable to genetic testing:

BRCA-Related Cancer Risk Assessment (Grade B — 2019, updated 2023): The USPSTF recommends that primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer, or ancestral background associated with BRCA1/2 mutations. Those who screen positive should receive genetic counseling and, if indicated, BRCA testing — covered without cost-sharing under ACA.

The 2022 Braidwood ruling (N.D. Texas) challenged the USPSTF mandate's constitutionality for recommendations issued after 2010. This ruling is actively litigated and does not definitively invalidate coverage. Many insurers continue to provide coverage as legally required. Cite the USPSTF recommendation in your appeal regardless — the insurer must address it.

NCCN Guidelines: The Clinical Gold Standard

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines include detailed criteria for genetic/familial high-risk assessment for breast and ovarian cancer, colorectal cancer, and other hereditary syndromes. These guidelines are updated regularly and represent consensus from cancer specialists at major cancer centers.

Key NCCN recommendations:

• BRCA1/2 testing is recommended for individuals meeting specific personal or family history criteria, including first- or second-degree relatives with known BRCA mutation, early-onset breast cancer (before age 50), triple-negative breast cancer, ovarian cancer, and Ashkenazi Jewish ancestry with any breast or ovarian cancer
• Lynch syndrome testing is recommended based on Amsterdam II criteria, revised Bethesda guidelines, or identification of mismatch repair deficiency in tumor tissue
• Multi-gene panels are appropriate when a single-gene test is indicated and the panel adds clinical value

NCCN criteria are generally broader than many insurer coverage policies. When an insurer denies testing that an NCCN guideline supports, document the specific NCCN criteria met by the patient.

BRCA Testing and Ashkenazi Jewish Ancestry

For women of Ashkenazi Jewish descent, the frequency of BRCA1/2 founder mutations (approximately 1 in 40 individuals carry a mutation) is substantially higher than the general population. The USPSTF, NCCN, and ACOG all recognize Ashkenazi Jewish ancestry as an independent risk factor warranting testing referral. This should be explicitly documented in the appeal.

The cost of BRCA testing has dropped significantly following the 2013 Supreme Court ruling in AMP v. Myriad Genetics, which invalidated gene patents. Testing is now available from multiple laboratories at $250–$400 — far less than the cost of a missed hereditary cancer diagnosis. This cost reduction strengthens medical necessity arguments.

Cascade Testing Appeals

When a pathogenic BRCA1/2 or other hereditary cancer variant is identified in one family member, testing first- and second-degree relatives (cascade testing) is critical. Cascade testing is cost-effective and clinically endorsed by NCCN, ACMG (American College of Medical Genetics and Genomics), and ASCO (American Society of Clinical Oncology).

For cascade testing denials:

• Document the index case (relative) with the known pathogenic variant
• Cite specific NCCN and ACMG recommendations for cascade testing
• Explain the clinical consequence of failing to identify the variant in the at-risk relative (missed opportunity for risk reduction surgery, enhanced surveillance, chemoprevention)

Step-by-Step Appeal Strategy

Step 1: Identify the specific denial reason. Is it a personal history criteria failure, family history not meeting threshold, panel testing classified as investigational, or a preventive vs. diagnostic coverage routing issue? Each requires a different argument.

Step 2: Obtain a letter from a genetic counselor or ordering physician. This letter should:

• Document the specific personal and family history meeting NCCN criteria
• Explain the clinical rationale for the specific test ordered (single-gene vs. multi-gene panel)
• Note the genetic counseling that was provided or recommended
• Cite the specific NCCN criteria met and the USPSTF Grade B recommendation (for BRCA)

Step 3: Invoke the ACA preventive care mandate for BRCA. For women with risk factors meeting USPSTF criteria, cite ACA Section 2713 and the USPSTF B recommendation. Request that the insurer provide a written explanation of how they are complying with this mandate.

Step 4: Challenge "investigational" classifications for multi-gene panels. Cite NCCN guidelines and ACMG standards supporting panel testing. Note that panels are standard of care at major academic medical centers and cancer programs nationwide.

Step 5: Request External Independent Review: Complete Guide" class="auto-link">external review. Genetic testing denials that conflict with NCCN guidelines or USPSTF recommendations are frequently overturned on external review. Request a reviewer with genetics or oncology expertise.

Supporting Evidence to Gather

• Genetic counselor or oncologist evaluation documenting personal and family history
• Pedigree (family tree with cancer diagnoses, ages, and relationships)
• Prior genetic testing results if any
• Known variant documentation from affected relatives (for cascade testing)
• NCCN genetic testing criteria (nccn.org — free registration required)
• USPSTF BRCA risk recommendation (Grade B)
• ACMG and ASCO position statements on hereditary cancer testing
• ACA Section 2713 and USPSTF preventive care coverage requirements

Fight Back With ClaimBack

A denied genetic test could mean a missed cancer diagnosis for you or a family member. ClaimBack helps you build a medically grounded appeal using NCCN guidelines, USPSTF recommendations, and your specific family history — quickly and thoroughly.

Start your genetic testing appeal today

Related Reading

• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied
• How to Write an Insurance Appeal Letter